Enzolytics, Inc. (OTC: ENZC) experienced significant stock price volatility and regulatory scrutiny typical of over-the-counter micro-cap equities. After periods of intense speculative retail interest surrounding proposed biotechnology and antiviral developments, the stock faced extended downward corrections, thin trading liquidity, and challenges in maintaining sustained commercial revenue milestones, leaving it heavily discounted.